Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion and GSK to collaborate on almorexant

Actelion and GSK to collaborate on almorexant

14th July 2008

Actelion and GlaxoSmithKline (GSK) have signed exclusive worldwide collaboration agreement for the development of almorexant as a treatment for sleep disorders.

The compound from Actelion is an orexin receptor antagonist currently in phase III development with first-in-class potential as a treatment for primary insomnia.

Under the terms of the agreement, Actelion will continue to lead the continuing registration and development programme for the compound in primary insomnia, with 40 per cent of the costs in this indication contributed by GSK.

GSK will also receive the exclusive rights worldwide for the co-development and commercialisation of almorexant.

Costs related to the study of the compound in other orexin-related disorders will be shared equally between the companies.

GSK will pay Actelion an initial fee of 150 million Swiss francs (66 million pounds) with the company eligible for further payments of up to 415 million Swiss francs.

Jean-Paul Clozel, chief executive officer of Actelion, said: “Almorexant has the potential to fundamentally change the treatment of sleep disorders.”

He added that GSK is an ideal partner to bring this compound to insomnia patients worldwide.

In September 2007, Actelion presented trial data to the World Sleep Congress in Australia, showing that almorexant improves sleep efficiency dependent on dose.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.